Shree Pacetronix Board Approves Warrant Conversion, Boosts Capital

Shree Pacetronix's total paid-up equity share capital has risen to ₹3.75 crore following the board's approval to allot 75,150 equity shares. The shares were issued to Akash Sethi at an issue price of ₹81 per share.

Reader Takeaway: Capital base expands via warrant conversion; deployment of funds for growth remains key.

Today's Filing Details

The Board of Directors of Shree Pacetronix Ltd. met on March 20, 2026, to approve the allotment of 75,150 equity shares. These shares result from the conversion of warrants previously issued to Akash Sethi. The allotment was made at an issue price of ₹81 per equity share. This transaction increases the company's total issued, subscribed, and paid-up equity share capital to ₹3.75 crore. The new equity shares, carrying a face value of ₹10 each, rank equally with the existing equity shares of the company. Following this allotment, Akash Sethi holds 4.35% of the company's shares.

Significance of the Capital Boost

This capital infusion strengthens Shree Pacetronix's financial position. An increased paid-up capital can support future operational expansions, debt servicing, or working capital needs. It also signals confidence from key stakeholders, like Akash Sethi, in the company's future prospects. The shift in shareholding pattern, with Akash Sethi becoming a significant minority shareholder, may indicate a commitment to growth funded by these new resources.

Background: Previous Capital Moves

Shree Pacetronix has a history of involving Akash Sethi in its capital raising efforts. In November 2025, Akash Sethi acquired 75,150 equity shares and 2,25,450 warrants through a preferential allotment. This followed the company announcing the allotment of 2,25,450 fully convertible equity warrants at an exercise price of ₹81 each in November 2025. The company had also previously announced the issuance of 1,50,000 warrants in December 2023 at ₹70 per warrant. These actions highlight Shree Pacetronix's strategy of using warrants and equity issuances to bolster its capital base.

Key Changes for the Company

• The company's equity share capital base has grown to ₹3.75 crore.
• Akash Sethi's shareholding in Shree Pacetronix now stands at 4.35%.
• The total number of outstanding equity shares has increased.
• Fresh capital is now available for business growth initiatives.

Investor Watchlist: Risks and Considerations

While SEBI confirmed no outstanding penalties against Shree Pacetronix as of October 2025, the company has faced supply contract disputes. An example includes a Calcutta High Court case in 2017 concerning alleged supply delays. The current capital increase is a positive step, but effective deployment of funds and continued operational performance remain crucial for long-term success.

Market Context: Peers and Competition

Shree Pacetronix operates in the medical devices sector, manufacturing pacemakers. Competitors such as Poly Medicure Ltd. are also active in this space, offering a broad range of medical and surgical equipment. Larger global companies like Globus Medical and Edwards Lifesciences compete in advanced therapeutic devices. Their capital structures and growth strategies provide benchmarks for Shree Pacetronix.

What to Watch For Next

Investors will be tracking the company's utilization of the funds raised from the warrant conversion. Future announcements regarding expansion plans or new product developments will be important. Shareholding patterns disclosed in subsequent filings and the performance of Akash Sethi's stake, along with his potential future involvement, are also key areas. Market reaction to the increased equity base and the stock's price movement will be closely monitored.